Wall Street brokerages forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will report $59.43 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $76.70 million and the lowest is $14.30 million. Crispr Therapeutics reported sales of $120,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 49,425%. The firm is scheduled to issue its next earnings report on Monday, February 24th.
On average, analysts expect that Crispr Therapeutics will report full year sales of $272.00 million for the current fiscal year, with estimates ranging from $226.90 million to $289.27 million. For the next financial year, analysts anticipate that the firm will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
Several analysts have recently commented on CRSP shares. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Oppenheimer increased their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Chardan Capital reaffirmed a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Finally, Goldman Sachs Group upped their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $69.54.
Shares of NASDAQ:CRSP traded up $1.66 on Wednesday, reaching $72.37. The company’s stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The company has a 50-day simple moving average of $54.81 and a 200 day simple moving average of $47.38. The company has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in shares of Crispr Therapeutics in the 3rd quarter valued at about $4,366,000. Orbimed Advisors LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth about $21,167,000. Granahan Investment Management Inc. MA lifted its stake in shares of Crispr Therapeutics by 8.3% during the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock worth $1,418,000 after purchasing an additional 2,655 shares in the last quarter. Barclays PLC lifted its position in shares of Crispr Therapeutics by 42.7% during the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock worth $568,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in shares of Crispr Therapeutics by 18.0% in the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock worth $400,000 after buying an additional 1,491 shares during the last quarter. Institutional investors and hedge funds own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Sell-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.